CI / The Cigna Group - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2026 The Cigna Group (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2026 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Number

David M. Cordani

Exhibit 10.2 David M. Cordani Chairman and CEO February 25, 2026 Brian Evanko Dear Brian: I am pleased to confirm that the Board of Directors has approved the following changes to your compensation package effective July 1, 2026 (the “Effective Date”), in connection with the assumption of your role as the next Chief Executive Officer of The Cigna Group: •Base Salary – Your base salary will increas

TERMS AND CONDITIONS OF YOUR [YEAR] GRANT OF STRATEGIC PERFORMANCE SHARES

Exhibit 10.7 The Cigna Group Cigna Long-Term Incentive Plan: Strategic Performance Share Grant Agreement The Cigna Group (“Cigna”) has granted you the number of strategic performance shares set forth below in this Strategic Performance Share Grant Agreement (“Strategic Performance Share Grant” or “Grant”) under the Cigna Long-Term Incentive Plan (“Plan”). The date of your Strategic Performance Sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exac

TERMS AND CONDITIONS OF YOUR [YEAR] GRANT OF STRATEGIC PERFORMANCE SHARES

Exhibit 10.4 The Cigna Group Cigna Long-Term Incentive Plan: Strategic Performance Share Grant Agreement The Cigna Group (“Cigna”) has granted you the number of strategic performance shares set forth below in this Strategic Performance Share Grant Agreement (“Strategic Performance Share Grant” or “Grant”) under the Cigna Long-Term Incentive Plan (“Plan”). The date of your Strategic Performance Sha

Eric Wiseman

Exhibit 10.1 Eric Wiseman Lead Independent Director February 25, 2026 David Cordani Dear David: I am pleased to confirm that the Board of Directors has approved the following changes to your compensation package effective July 1, 2026 (the “Effective Date”), in connection with the assumption of your role as Executive Chair of The Cigna Group: •Base Salary – Your base salary will increase to a pre-

The Cigna Group Reports Strong First Quarter 2026 Results, Raises 2026 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong First Quarter 2026 Results, Raises 2026 Outlook • Total revenues for the first quarter 2026 increased 5% to $68.5 billion • Shareholders’ net income for the first quarter 2026 w

TERMS AND CONDITIONS OF YOUR [YEAR] RESTRICTED STOCK GRANT

Exhibit 10.5 The Cigna Group Cigna Long-Term Incentive Plan: Restricted Stock Grant Agreement The Cigna Group (“Cigna”) has granted you the number of shares of restricted stock of Cigna set forth below in this Restricted Stock Grant Agreement (“Restricted Stock Grant” or “Grant”) under the Cigna Long-Term Incentive Plan (“Plan”). The date of your Restricted Stock Grant (“Grant Date”) and the dates

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 The Cigna Group (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Num

THE CIGNA GROUP CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT

Exhibit 10.6 THE CIGNA GROUP CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT In consideration of The Cigna Group and/or its affiliates, subsidiaries, successors, assigns, or related companies or entities (collectively the “Company”) employing me, compensating me, providing me with access to Confidential Information, and/or access to the Company's customers and clients and the oppor

TERMS AND CONDITIONS OF YOUR [YEAR] GRANT OF A NONQUALIFIED STOCK OPTION

Exhibit 10.3 The Cigna Group Cigna Long-Term Incentive Plan: Nonqualified Stock Option Grant Agreement The Cigna Group (“Cigna”) has granted you the option to purchase the number of shares of Cigna Common Stock set forth below in this Option Grant Agreement (“Option Grant”) under the Cigna Long-Term Incentive Plan (“Plan”). The date of your Option Grant (“Grant Date”), the dates on which your Opti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 The Cigna Group (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

ARS

THE CIGNA GROUP 2025 ANNUAL REPORT OUR COMMITMENT TO BETTERTO IMPROVE THE HEALTH AND VITALITY OF THOSE WE SERVE OUR MISSIONCHARTING A BETTER PATH FOR OUR CUSTOMERS AND PATIENTS The global health care system has created breakthrough innovations and helped people and families get access to the care and support they need.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2026 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2026 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File N

1

Exhibit 99.1 The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer • Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of Directors • Evanko elected to the company’s Board of Directors • Company reaffirms 2026 Financial Outlook BLOOMFIELD, Conn., Mar. 3, 2026 – The Cigna G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2026 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2026 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File N

Listed below are subsidiaries of The Cigna Group as of December 31, 2025 with their jurisdictions of organization. Those subsidiaries not listed would not, in the aggregate, constitute a “significant subsidiary” of The Cigna Group, as that term is de

Exhibit 21 Exhibit 21 – Subsidiaries of the Registrant Listed below are subsidiaries of The Cigna Group as of December 31, 2025 with their jurisdictions of organization.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 The Cigna Group

The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results, Establishes 2026 Outlook and Increases Dividend

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results, Establishes 2026 Outlook and Increases Dividend • Total revenues for 2025 increased 11% to $274.9 billion • Shareholders’ net income f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2026 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2026 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 22, 2025 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 22, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2025 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

The Cigna Group Reports Strong Third Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Third Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook • Total revenues for the third quarter 2025 increased 10% to $69.7 billion • Shareholders’ net income for the thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2025 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

144

144 0001722909 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Evanko Brian C Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 5368 1610400.

SUPPLEMENTAL INDENTURE NO. 8

Exhibit 4.1 Execution Version SUPPLEMENTAL INDENTURE NO. 8 THIS SUPPLEMENTAL INDENTURE NO. 8, dated as of September 4, 2025 (this “Supplemental Indenture”), between THE CIGNA GROUP, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association duly organized and existing under the

$1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036 $750,000,000 6.000% Senior Notes due 2056 Underwriting Agreement

Exhibit 1.1 $1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036 $750,000,000 6.000% Senior Notes due 2056 Underwriting Agreement September 2, 2025 BofA Securities, Inc. One Bryant Park New York, New York 10036 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 HSBC Securities (USA) Inc. 66 Huds

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 4, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File N

CALCULATION OF FILING FEES TABLE (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter)

Exhibit 107 CALCULATION OF FILING FEES TABLE 424(b)(5) (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter) The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings.

The Cigna Group $1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036  $750,000,000 6.000% Senior Notes due 2056

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(5) Registration No. 333-289983 PROSPECTUS SUPPLEMENT (To Prospectus dated September 2, 2025) $4,500,000,000   The Cigna Group $1,000,000,000 4.500% Senior Notes due 2030 $1,250,000,000 4.875% Senior Notes due 2032 $1,500,000,000 5.250% Senior Notes due 2036  $750,000,000 6.000% Senior Notes due 2056 We are offering $1,000,000,000 of our 4.500% Senior

THE CIGNA GROUP Pricing Term Sheet September 2, 2025

Free Writing Prospectus (to the Preliminary Prospectus Supplement dated September 2, 2025) Filed Pursuant to Rule 433 Registration Statement No.

As filed with the Securities and Exchange Commission on September 2, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 2, 2025 Registration No.

Calculation of Filing Fee Tables Form S-3 (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter)

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) The Cigna Group (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type C

SUBJECT TO COMPLETION, DATED SEPTEMBER 2, 2025

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

SECURITIES AND EXCHANGE COMMISSION

Exhibit 25 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2)☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File N

The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook • Total revenues for the second quarter 2025 increased 11% to $67.2 billion • Shareholders’ net income for the s

Agreement and Release between The Cigna Group and Eric Palmer dated April 15, 2025

Exhibit 10.1 AGREEMENT AND RELEASE This Agreement and Release is dated March 10, 2025, and is between Eric Palmer (you), and the Company. You and the Company (defined below) intend to be legally bound by the Agreement and are entering into it in reliance on the promises made to each other in this Agreement. Under the Agreement, your employment will end, and you and the Company agree to settle all

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2025 The Cigna Group (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numbe

Revolving Credit and Letter of Credit Agreement, dated as of April 24, 2025, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, and BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc. and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners

exh102cigna-5xyearrevol Exhibit 10.2 ═══════════════════════════════════════ REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 24, 2025 Among THE CIGNA GROUP, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ═══════════════════════════════════════ JPMORGAN CHASE BANK, N.A., BofA SECURITIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A.Full title of the plan and the addre

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499189

The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors

Exhibit 99.1 The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors BLOOMFIELD, Conn., June 2, 2025 – Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2. Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Number

The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook

Exhibit 99.1 INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook • Total revenues for the first quarter 2025 increased 14% to $65.5 billion • Shareholders’ net income for the first quarter 2025 was $1.3 billi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 The Cigna Group (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Number)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Num

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 19, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numb

The Cigna Group Completes Sale of Medicare Businesses to HCSC

Exhibit 99.1 The Cigna Group Press Release The Cigna Group Completes Sale of Medicare Businesses to HCSC BLOOMFIELD, Conn., March 19, 2025 – Global health company The Cigna Group (NYSE: CI) today announced the successful completion of the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC). The divestment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒

ARS

THE CIGNA GROUP 2024 ANNUAL REPORT Performance Purpose THE CIGNA GROUP 2024 ANNUAL REPORTPURPOSE AND PERFORMANCE: MEMPHIS SPOTLIGHTTHE CIGNA GROUP 2024 ANNUAL REPORT 2 THE CIGNA GROUP 2024 ANNUAL REPORT Improving the health and vitality of those we serve has never been more important.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numb

144

144 0001691704 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Eder Noelle K Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 9944 3182080.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2025 The Cigna Group (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Numbe

The Cigna Group Non-Employee Director Compensation Program, amended and restated effective July 24, 2024

Exhibit 10.14(c) The Cigna Group Non-Employee Director Compensation Program I. Board and Committee Retainers A. Annual Board Retainer. Each non-employee director of The Cigna Group (“Director”), with the exception of the Chair of the Board of Directors, receives $335,000 annually for Board membership (“Annual Board Retainer”). A portion ($120,000) of the Annual Board Retainer is paid in cash and t

Subsidiaries of the Registrant

Exhibit 21 Exhibit 21 – Subsidiaries of the Registrant Listed below are subsidiaries of The Cigna Group as of December 31, 2024 with their jurisdictions of organization.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 The Cigna Group

Securities Transactions and Insider Trading Policy

Exhibit 19.1 I. General Description Title: Securities Transactions and Insider Trading Effective Date: October 18, 2022 Prepared By/ Last Revised By: Office of the Corporate Secretary Regulation: SEC Rule 10b-5 II. Purpose and Scope Purpose: It is The Cigna Group's policy to comply with securities laws prohibiting insider trading, to establish standards of conduct for employees and others who obta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2025 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2025 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

The Cigna Group Reports Fourth Quarter and Full Year 2024 Results, Establishes 2025 Outlook and Increases Dividend

Exhibit 99.1 INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Fourth Quarter and Full Year 2024 Results, Establishes 2025 Outlook and Increases Dividend • Total revenues for 2024 increased 27% to $247.1 billion • Shareholders’ net income for 2024 was $3.4 bill

LETTER

January 29, 2025 Brian C. Evanko Chief Financial Officer The Cigna Group 900 Cottage Grove Road Bloomfield, CT 06002 Re: The Cigna Group Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-38769 Dear Brian C. Evanko: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notw

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002 VIA EDGAR January 16, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.

LETTER

December 20, 2024 Brian C. Evanko Chief Financial Officer The Cigna Group 900 Cottage Grove Road Bloomfield, CT 06002 Re: The Cigna Group Form 10-K for the Fiscal Year Ended December 31, 2023 Form 10-Q for the Quarterly Period Ended June 30, 2024 Response dated November 21, 2024 File No. 001-38769 Dear Brian C. Evanko: We have reviewed your November 21, 2024 response to our comment letter and have

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002

THE CIGNA GROUP 900 Cottage Grove Road Bloomfield, Connecticut 06002 VIA EDGAR November 21, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.

CI / The Cigna Group / FMR LLC Passive Investment

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 CIGNA GROUP (THE) COMMON STOCK Cusip #125523100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #125523100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 10,956,316 Item 6: 0 Item 7: 14,193,987 Item 8: 0 Item 9: 1

The Cigna Group Reports Strong Third Quarter 2024 Results, Reaffirms 2024 Adjusted EPS Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Third Quarter 2024 Results, Reaffirms 2024 Adjusted EPS Outlook • Total revenues for the third quarter 2024 increased 30% to $63.7 billion • Shareholders’ net income for the thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (

LETTER

October 22, 2024 Brian C. Evanko Chief Financial Officer The Cigna Group 900 Cottage Grove Road Bloomfield, CT 06002 Re: The Cigna Group Form 10-K for the Fiscal Year Ended December 31, 2023 Form 10-Q for the Quarterly Period Ended June 30, 2024 File No. 001-38769 Dear Brian C. Evanko: We have limited our review of your filing to the financial statements and related disclosures and have the follow

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 3, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exact

The Cigna Group Reports Strong Second Quarter 2024 Results

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Second Quarter 2024 Results • Total revenues for the second quarter 2024 increased 25% to $60.5 billion • Shareholders’ net income for the second quarter 2024 was $1.5 billion,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A.Full title of the plan and the addre

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

144

144 0001625579 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Granger Elder Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 1000 338080.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 The Cigna Group (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499189

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exac

The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook • Total revenues for the first quarter 2024 were $57.3 billion • Shareholders’ net loss for the first quarter 2024 was $0.3 billi

Revolving Credit and Letter of Credit Agreement, dated as of April 25, 2024, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc. and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners.

Exhibit 10.1 ═══════════════════════════════════════ REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 25, 2024 Among THE CIGNA GROUP, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ═══════════════════════════════════════ JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC., CITIBANK, N.A.,

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: The Cigna Group Name of persons relying on exemption: National Center for Public Policy Research Address of persons relying on exemption: 2005 Massachusetts Ave. N.W., Washington, D.C 20036 Written materials are submitted pursuant to Rule 14a-6(g) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

144

144 0001318751 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Cordani David Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 6338 2250682.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

ARS

. . Healthy Today Building a Better Tomorrow THE CIGNA GROUP 2023 ANNUAL REPORT1. The Cigna Group Newsroom, Vitality 2023: Americans are optimistic despite facing physical, mental, and financial health challenges, October 25, 2023. 2. The Cigna Group Newsroom, The Cigna Group Reports Strong Fourth Quarter and Full Year 2023 Results, Raises 2024 Adjusted EPS Outlook, and Increases Dividend, Februar

144

144 0001318751 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Cordani David Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 13761 4779541.

The Cigna Group Raises Long-Term Growth Target, and Launches New Innovative Solutions at 2024 Investor Day

Exhibit 99.1 PRESS RELEASE The Cigna Group Raises Long-Term Growth Target, and Launches New Innovative Solutions at 2024 Investor Day Highlights: · Raises long-term average annual adjusted EPS1 growth target to 10%-14% · Affirms 2024 adjusted EPS1 guidance of at least $28.25 · Announces solutions and innovations for some of the greatest health care challenges: GLP-1 spend, mental health care acces

144

144 0001318751 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Cordani David Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2412 833892.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

Offer Letter for Eric P. Palmer dated January 16, 2024

Exhibit 10.23 David M. Cordani Chairman and CEO January 16, 2024 Eric Palmer Dear Eric: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective February 5, 2024 in connection with the assumption of your expanded role as EVP, Enterprise Strategy and President & CEO Evernorth: Base Salary – Your base salary will rema

Offer letter for Brian Evanko dated January 16, 2024

Exhibit 10.26 David M. Cordani Chairman and CEO January 16, 2024 Brian Evanko Dear Brian: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective February 5, 2024 in connection with the assumption of your expanded role as EVP, CFO and President & CEO Cigna Healthcare: Base Salary – Your base salary will increase to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 The Cigna Group

Incentive Compensation Clawback Policy

Exhibit 97.1 The Cigna Group Incentive Compensation Clawback Policy (As Adopted on October 25, 2023 Pursuant to NYSE Rule 303A.14) 1.Overview. The Board of Directors (the “Board”) of The Cigna Group (the “Company”) has adopted this Incentive Compensation Clawback Policy (the “Policy”) which requires the recoupment of certain incentive-based compensation in accordance with the terms herein and is i

Subsidiaries of the Registrant

Exhibit 21 Exhibit 21 – Subsidiaries of the Registrant Listed below are subsidiaries of The Cigna Group as of December 31, 2023 with their jurisdictions of organization.

Description of Securities

Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of the material terms of the Common Stock, par value $0.01 per share of The Cigna Group (“Cigna” or the “Company”). This summary is not complete and is qualified by Cigna’s restated certificate of incorporation, which we refer to as the certific

144

144 0001318751 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Cordani David Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2000 690075.

The Cigna Group Announces $3.2 Billion Accelerated Stock Repurchase

Exhibit 99.1 Press Release The Cigna Group Announces $3.2 Billion Accelerated Stock Repurchase Bloomfield, Conn. February 15, 2024 – Global health company The Cigna Group (NYSE: CI) will repurchase $3.2 billion of common stock through accelerated stock repurchase agreements (the “ASR Agreements”) with Deutsche Bank AG and Bank of America, N.A. (the “Counterparties”). The ASR Agreements are part of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

CI / The Cigna Group / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0605-cignagroupthe.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Cigna Group/The Title of Class of Securities: Common Stock CUSIP Number: 125523100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the r

between The Cigna Group and U.S. Bank Trust Company, National Association, as trustee

Exhibit 4.1 SUPPLEMENTAL INDENTURE NO. 7 THIS SUPPLEMENTAL INDENTURE NO. 7, dated as of February 13, 2024 (this “Supplemental Indenture”), between THE CIGNA GROUP, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association duly organized and existing under the laws of the Unite

CI / The Cigna Group / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.1 CIGNA GROUP (THE) COMMON STOCK Cusip #125523100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #125523100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,054,714 Item 6: 0 Item 7: 14,521,157 Item 8: 0 Item 9: 14,521,157 Item 11: 4

The Cigna Group $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(5) Registration No. 333-268633 Prospectus Supplement (To Prospectus dated December 1, 2022) $4,500,000,000   The Cigna Group $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054 We are offering $1,000,000,000 of our 5.000% Senior N

$1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054 Underwriting Agreement

Exhibit 1.1 Execution Version $1,000,000,000 5.000% Senior Notes due 2029 $750,000,000 5.125% Senior Notes due 2031 $1,250,000,000 5.250% Senior Notes due 2034 $1,500,000,000 5.600% Senior Notes due 2054 Underwriting Agreement February 5, 2024 Deutsche Bank Securities Inc. 1 Columbus Circle New York, New York 10019 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 J.P. Morgan Securi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

CALCULATION OF FILING FEES TABLE

Exhibit 107 CALCULATION OF FILING FEES TABLE The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings.

THE CIGNA GROUP Pricing Term Sheet February 5, 2024

Free Writing Prospectus (to the Preliminary Prospectus Supplement dated February 5, 2024) Filed Pursuant to Rule 433 Registration Statement No.

The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy t

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(3) Registration No. 333-268633 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not perm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

The Cigna Group Reports Strong Fourth Quarter and Full Year 2023 Results, Raises 2024 Adjusted EPS Outlook, and Increases Dividend

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Fourth Quarter and Full Year 2023 Results, Raises 2024 Adjusted EPS Outlook, and Increases Dividend • Total revenues for 2023 were $195.3 billion • Shareholders’ net income for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction of incorporation) (Commission File Nu

The Cigna Group to Sell Medicare Businesses and CareAllies to Health Care Service Corporation (HCSC) Transaction Expected to be Accretive to Adjusted EPS1 in 2025 The Cigna Group Reaffirms 2024 Outlook and Long-Term Adjusted EPS1 Growth Target of 10-

Exhibit 99.1 PRESS RELEASE The Cigna Group to Sell Medicare Businesses and CareAllies to Health Care Service Corporation (HCSC) Transaction Expected to be Accretive to Adjusted EPS1 in 2025 The Cigna Group Reaffirms 2024 Outlook and Long-Term Adjusted EPS1 Growth Target of 10-13% Bloomfield, Conn., Jan. 31, 2024 – Global health company The Cigna Group (NYSE: CI) today announced that it has entered

CI / The Cigna Group / BlackRock Inc. Passive Investment

SC 13G/A 1 us1255231003012524.txt us1255231003012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Cigna Corporation - (Name of Issuer) Common Stock - (Title of Class of Securities) 125523100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 10, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 10, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Intends to Repurchase at Least $5 Billion of Common Stock by End of First Half of 2024, with Portion Executed Via ASR in First Quarter 2024 Reaffirms Previously Provided Outlook for Full-Year 2023

Exhibit 99.1 The Cigna Group Announces Significant Increase to Share Repurchase Program of $10 Billion Intends to Repurchase at Least $5 Billion of Common Stock by End of First Half of 2024, with Portion Executed Via ASR in First Quarter 2024 Reaffirms Previously Provided Outlook for Full-Year 2023 BLOOMFIELD, Conn., Dec. 10, 2023 /PRNewswire/ - Global health company The Cigna Group (NYSE: CI) tod

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 4, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2023 The Cigna Group (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

Offer Letter for Nicole S. Jones dated September 14, 2023

exh102xnjonesxofferxlet David M. Cordani Chairman and CEO September 14, 2023 Nicole Jones Dear Nicole: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective September 14, 2023 in connection with the assumption of your expanded role as EVP, Chief Administrative Officer & General Counsel:  Base Salary – will incre

Raises 2023 Adjusted EPS, Revenue, and Cash Flow Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Third Quarter 2023 Results, Raises 2023 Adjusted EPS, Revenue, and Cash Flow Outlook • Total revenues in the third quarter were $49.0 billion • Shareholders’ net income for the thir

Offer Letter for Noelle K. Eder dated September 14, 2023

exh101xnederxofferxlett David M. Cordani Chairman and CEO September 14, 2023 Noelle Eder Dear Noelle: I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective September 14, 2023 in connection with the assumption of your expanded role as EVP Technology & Operations:  Base Salary – will increase to a pre-tax annualiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 14, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exact

Restated Certificate of Incorporation of The Cigna Group

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF THE CIGNA GROUP The undersigned hereby certifies on behalf of The Cigna Group as follows: 1. The present name of the corporation is The Cigna Group. The corporation was incorporated under the name "Halfmoon Parent, Inc." by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 6, 20

The Cigna Group Reports Strong Second Quarter 2023 Results

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong Second Quarter 2023 Results • Total revenues in the second quarter were $48.6 billion • Shareholders’ net income for the second quarter was $1.5 billion, or $4.92 per share • Adjust

144

144 0001722909 XXXXXXXX LIVE 0001739940 Cigna Group 001-38769 900 COTTAGE GROVE ROAD BLOOMFIELD CT 06002 8602266000 Evanko Brian C Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2307 692100.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A. Full title of the plan a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2023 The Cigna Group (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499189

Supplemental Pharmacy Benefit Management Model Disclosure

Exhibit 20.1 Supplemental Pharmacy Benefit Management Model Disclosure On each of April 13 and 20, 2023, Express Scripts, Inc. (“Express Scripts”) issued a press release announcing several actions to further evolve its pharmacy benefit management (“PBM”) model. The purpose of this disclosure is to provide additional information regarding Express Scripts’ business model that is described in the 202

The Cigna Group Reports Strong First Quarter 2023 Results, Raises 2023 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] The Cigna Group Reports Strong First Quarter 2023 Results, Raises 2023 Outlook • Total revenues in the first quarter were $46.5 billion • Shareholders’ net income for the first quarter was $1.3 billion, or $4.24

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2023 The Cigna Group (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898

Offer letter for Noelle Eder dated July 22, 202

ederofferletter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 The Cigna Group (Exac

Restated Certificate of Incorporation of the registrant effective as of April 26, 2023

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF THE CIGNA GROUP The undersigned hereby certifies on behalf of The Cigna Group as follows: 1. The present name of the corporation is The Cigna Group. The corporation was incorporated under the name "Halfmoon Parent, Inc." by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 6, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

The Cigna Group Announces Appointment of Dr. Philip Ozuah to Board of Directors

Exhibit 99.1 Press Release The Cigna Group Announces Appointment of Dr. Philip Ozuah to Board of Directors BLOOMFIELD, Conn., May 1, 2023 – Global health company The Cigna Group (NYSE:CI) today announced that Dr. Philip Ozuah has been appointed to the organization’s Board of Directors. His appointment is effective June 1, 2023. Since 2019, Dr. Philip Ozuah has served as the President and CEO of Mo

Revolving Credit and Letter of Credit Agreement, dated as of April 27, 2023, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc. and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners.

Exhibit 10.1 EXECUTION VERSION ═══════════════════════════════════════ REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 27, 2023 Among THE CIGNA GROUP, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ═══════════════════════════════════════ JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

DEFA14A 1 ny20008678x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of per

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of persons relying on exemption: 16 Beaver Meadow Rd, Norwich, VT 05055 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated under the

REMEMBER: You can vote your shares online or by telephone. Please use the control number found on the enclosed proxy card and visit www.proxyvote.com to submit your instructions online, or if you received this letter by email, you may simply click th

April 10, 2023 Dear Shareholder: We have previously sent to you proxy materials for The Cigna Group Annual Meeting of Shareholders to be held on April 26, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Ru

ARS

Connecting for a Healthier Future THE CIGNA GROUP 2022 ANNUAL REPORTOUR MISSION To improve the health and vitality of those we serveDAVID M.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

$700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033 Underwriting Agreement

Exhibit 1.1 $700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033 Underwriting Agreement February 28, 2023 BofA Securities, Inc. One Bryant Park New York, New York 10036 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 U.S. Bancorp Investments, Inc. 214 N. Tryon St., 26th Floor Charlotte, North Carolina 28202 as the Representatives of the several Underw

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2023 The Cigna Group (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

Sixth Supplemental Indenture, dated as of March 7, 2023, between Cigna Corporation and U.S. Bank National Association, as trustee

Exhibit 4.1 SUPPLEMENTAL INDENTURE NO. 6 THIS SUPPLEMENTAL INDENTURE NO. 6, dated as of March 7, 2023 (this “Supplemental Indenture”), between THE CIGNA GROUP, a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association duly organized and existing under the laws of the United St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rul

CALCULATION OF FILING FEES TABLE

EX-FILING FEES 2 ny20007738x3ex107.htm FILING FEES TABLE Exhibit 107 CALCULATION OF FILING FEES TABLE The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings. The maximum aggregate amount of those offerings is $1,499,234,000. Security Type Security Class Title Fee Calculation of Carry Forward Rule Amount Registered Proposed Maximum Offering Price

The Cigna Group $700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(5) Registration No. 333-268633 Prospectus Supplement (To Prospectus dated December 1, 2022) $1,500,000,000   The Cigna Group $700,000,000 5.685% Senior Notes due 2026 $800,000,000 5.400% Senior Notes due 2033 We are offering $700,000,000 of our 5.685% Senior Notes due 2026 (the “3-Year Notes”) and $800,000,000 of our 5.400% Senior Notes due 2033 (the

THE CIGNA GROUP Pricing Term Sheet February 28, 2023

Free Writing Prospectus (to the Preliminary Prospectus Supplement dated February 28, 2023) Filed Pursuant to Rule 433 Registration Statement No.

The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy t

TABLE OF CONTENTS Filed Pursuant to Rule 424(B)(3) Registration No. 333-268633 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not perm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2023 The Cigna Group

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

Amendment No.1 to the Cigna Long-Term Incentive Plan effective December 1, 2022

Exhibit 10.1(b) AMENDMENT NO. 1 TO THE CIGNA LONG-TERM INCENTIVE PLAN (Amended and Restated Effective as of April 28, 2021) WHEREAS, Cigna Corporation (“Cigna”), maintains the Cigna Long-Term Incentive Plan (Amended and Restated Effective as of April 28, 2021) (the “Plan”); and WHEREAS, under Section 16.1 of the Plan, the Board of Directors of Cigna (the “Board”) (or an authorized committee of the

Subsidiaries of the Registrant

Exhibit 21 – Subsidiaries of the Registrant Listed below are subsidiaries of The Cigna Group as of December 31, 2022 with their jurisdictions of organization.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 The Cigna Group

CI / Cigna Corp / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 ci13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Cigna Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 125523100 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to wh

CI / Cigna Corp / DODGE & COX - SC 13G/A Passive Investment

SC 13G/A 1 d390295dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Cigna Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 125523100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

Amended and Restated By-laws of The Cigna Group

Exhibit 3.3 AMENDED AND RESTATED BY-LAWS OF THE CIGNA GROUP (A Delaware Corporation) Article I Offices Section 1. Registered Office. The registered office of The Cigna Group (hereinafter, the “Corporation”) within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The Corporation may also have offices at such other places, both within and with

Restated Certificate of Incorporation of The Cigna Group

Exhibit 3.2 RESTATED CERTIFICATE OF INCORPORATION OF THE CIGNA GROUP The undersigned hereby certifies on behalf of The Cigna Group as follows: 1. The present name of the corporation is The Cigna Group. The corporation was incorporated under the name "Halfmoon Parent, Inc." by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 6, 20

Certificate of Amendment of Restated Certificate of Incorporation of Cigna Corporation

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CIGNA CORPORATION (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Cigna Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. The Restated Certificate of Incorporation of the

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2023 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4

CI / Cigna Corp / FMR LLC Passive Investment

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 CIGNA CORP COMMON STOCK Cusip #125523100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #125523100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 14,291,710 Item 6: 0 Item 7: 16,251,713 Item 8: 0 Item 9: 16,251,7

CI / Cigna Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Cigna Corp. Title of Class of Securities: Common Stock CUSIP Number: 125523100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

CI / Cigna Corp / BlackRock Inc. Passive Investment

SC 13G 1 us1255231003020723.txt us1255231003020723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Cigna Corporation - (Name of Issuer) Common Stock - (Title of Class of Securities) 125523100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2023 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend • Total revenues for 2022 were $180.5 billion • Shareholders’ net income for 2022 was $6.7 billion, or $21.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

As filed with the Securities and Exchange Commission on December 1, 2022

table of contents As filed with the Securities and Exchange Commission on December 1, 2022 Registration No.

securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to

Exhibit 25 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) [] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Em

Calculation of Filing Fee Tables Form S-3 (Form Type) Cigna Corporation. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

EX-FILING FEES 5 ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cigna Corporation. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 30, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 Cigna Corporation

Cigna Reports Strong Third Quarter 2022 Results, Raises 2022 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong Third Quarter 2022 Results, Raises 2022 Outlook ? Total revenues in the third quarter were $45.3 billion ? Shareholders? net income for the third quarter was $2.8 billion, or $8.97 per share ? Adjust

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Restated By-Laws of Cigna Corporation dated October 26, 2022

Exhibit 3.2 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) Article I Offices Section 1. Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 Cigna Corporation (Exa

Cigna Reports Strong Second Quarter 2022 Results, Raises 2022 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong Second Quarter 2022 Results, Raises 2022 Outlook ? Total revenues in the second quarter were $45.5 billion ? Shareholders? net income for the second quarter was $1.6 billion, or $4.90 per share ? Adj

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 A. Full title of the plan a

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-499

Cigna Announces $3.5 Billion Accelerated Stock Repurchase Agreements

Exhibit 99.1 Press Release Cigna Announces $3.5 Billion Accelerated Stock Repurchase Agreements Bloomfield, Conn. June 16, 2022 ? Global health services company Cigna Corporation (NYSE: CI) will repurchase $3.5 billion of common stock through accelerated stock repurchase agreements (the ?ASR Agreements?) with Mizuho Markets Americas LLC and Morgan Stanley & Co. LLC (the ?Counterparties?). The ASRs

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991

Cigna Reports Strong First Quarter 2022 Results, Raises 2022 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 860-787-7968 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Strong First Quarter 2022 Results, Raises 2022 Outlook ? Total revenues in the first quarter were $44.0 billion, and adjusted revenues1 were $44.1 billion ? Shareholders? net income for the first quarter wa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission Fil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49918

Press release dated May 6, 2022.

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38769 Cigna Corporation (Ex

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Emp

Revolving Credit and Letter of Credit Agreement, dated as of April 28, 2022, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc., MUFG Bank, LTD and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners

Exhibit 10.1 Execution Version ??????????????????????????????????????? REVOLVING CREDIT AND LETTER OF CREDIT AGREEMENT Dated as of April 28, 2022 Among CIGNA CORPORATION, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, THE BANKS FROM TIME TO TIME PARTY HERETO, and JPMORGAN CHASE BANK, N.A., as Administrative Agent ??????????????????????????????????????? JPMORGAN CHASE BANK, N.A., BofA SECURITIES, I

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-49

SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NOTICE OF EXEMPT SOLICITATION

SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Cigna Corporation NAME OF PERSONS RELYING ON EXEMPTION: Proxy Impact ADDRESSES OF PERSONS RELYING ON EXEMPTION: 5011 Esmond Ave., Richmond, CA 94805 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of

YOUR VOTE IS IMPORTANT: You can vote your shares online or by telephone. Please use the control number found on the enclosed proxy card and visit www.proxyvote.com to submit your instructions online; or if you received this letter by email, you may s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ??? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of per

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Cigna Corporation Name of persons relying on exemption: Clean Yield Asset Management Address of persons relying on exemption: 16 Beaver Meadow Rd, Norwich, VT 05055 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated under the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ??? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitt

Advisory Services Agreement by and between Cigna Corporation and Matthew Manders, dated November 3, 2021

Exhibit 10.36(c) ADVISORY SERVICES AGREEMENT This Advisory Services Agreement (?Agreement?) is made as of November 3, 2021 between Cigna Corporation (?Company?), and Matthew Manders (?Advisor?) (Company and Advisor together, the ?Parties?). WHEREAS, the Company has determined that it is in its best interests to have Advisor provide the Company with services as an Advisor during the Advisory Period

Executive Retirement Agreement by and between Cigna Corporation and Mr. Timothy Wentworth, dated as of November 3, 2021

Exhibit 10.30(b) EXECUTIVE RETIREMENT AGREEMENT This Executive Retirement Agreement is dated as of November 3, 2021, and is between Timothy Wentworth (you), and the Company. You and the Company (defined below) intend to be legally bound by the Agreement, and are entering into it in reliance on the promises made to each other in this Agreement. Under the Agreement, your employment will end, and you

Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective April 1, 2022

Exhibit 10.17(b) Cigna Corporation Non-Employee Director Compensation Program I. Board and Committee Retainers A. Annual Board Retainer. Each non-employee director of Cigna Corporation (?Director?), with the exception of the Chair of the Board of Directors, receives $310,000 annually for Board membership (?Annual Board Retainer?). A portion ($120,000) of the Annual Board Retainer is paid in cash a

Subsidiaries of the Registrant

Exhibit 21 ? Subsidiaries of the Registrant Listed below are subsidiaries of Cigna Corporation as of December 31, 2021 with their jurisdictions of organization.

Executive Retirement Agreement by and between Cigna Corporation and Matthew Manders, dated November 3, 2021

Exhibit 10.36(b) EXECUTIVE RETIREMENT AGREEMENT This Executive Retirement Agreement is dated as of November 3, 2021, and is between Matthew Manders (you), and the Company. You and the Company (defined below) intend to be legally bound by the Agreement, and are entering into it in reliance on the promises made to each other in this Agreement. Under the Agreement, your employment will end, and you a

Advisory Services Agreement by and between Cigna Corporation and Mr. Timothy Wentworth, dated as of November 3, 2021

Exhibit 10.30(c) ADVISORY SERVICES AGREEMENT This Advisory Services Agreement (?Agreement?) is made as of November 3, 2021 between Cigna Corporation (?Company?), and Timothy Wentworth (?Advisor?) (Company and Advisor together, the ?Parties?). WHEREAS, the Company has determined that it is in its best interests to have Advisor provide the Company with services as an Advisor during the Advisory Peri

Amended and Restated By-Laws of the registrant as last amended February 22, 2022

Exhibit 3.2 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) Article I Offices Section 1.Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2.Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of Di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38769 Cigna Corporati

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective January 1, 2022

Exhibit 10.17(a) Cigna Corporation Non-Employee Director Compensation Program I. Board and Committee Retainers A. Annual Board Retainer. Each non-employee director of Cigna Corporation (?Director?), with the exception of the Chair of the Board of Directors, receives $310,000 annually for Board membership (?Annual Board Retainer?). A portion ($120,000) of the Annual Board Retainer is paid in cash a

CI / Cigna Corp / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Cigna Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 125523100 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed:

CI / Cigna Corp / DODGE & COX - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0)* Cigna Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 125523100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

CI / Cigna Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Cigna Corp. Title of Class of Securities: Common Stock CUSIP Number: 125523100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

CI / Cigna Corp / FMR LLC Passive Investment

SCHEDULE 13G Amendment No. 1 CIGNA CORP COMMON STOCK Cusip #125523100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #125523100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,481,239 Item 6: 0 Item 7: 15,722,330 Item 8: 0 Item 9: 15,722,330 Item 11: 4.743% I

Cigna Reports Fourth Quarter and Full Year 2021 Results, Expects Continued Revenue and Attractive Earnings Per Share Growth in 2022

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Ralph Giacobbe 804-688-3400 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Fourth Quarter and Full Year 2021 Results, Expects Continued Revenue and Attractive Earnings Per Share Growth in 2022 ? Total revenues for 2021 were $174.1 billion, and adjusted revenues1 for 2021 were $174

CI / Cigna Corp / BlackRock Inc. Passive Investment

us1255231003020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) Cigna Corporation - (Name of Issuer) Common Stock - (Title of Class of Securities) 125523100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2022 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware 001-38769 82-4991898 (State or other jurisdiction (Commission file number) (I.R.S

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 27, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Amended and Restated By-Laws of Cigna Corporation, dated as of December 2, 2021.

Exhibit 3.1 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) Article I Offices Section 1. Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS E

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-38769 Cigna Corporation (

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-

Cigna Reports Third Quarter 2021 Results, Raises 2021 Outlook

Exhibit 99.1 Press Release INVESTOR RELATIONS CONTACT: Alexis Jones 215-761-3637 [email protected] MEDIA CONTACT: Justine Sessions 860-810-6523 [email protected] Cigna Reports Third Quarter 2021 Results, Raises 2021 Outlook ? Total revenues in the third quarter were $44.3 billion, and adjusted revenues1 were $44.3 billion ? Shareholders? net income for the third quarter was $1.6 bill

Amended and Restated By-Laws of Cigna Corporation as last amended

Exhibit 3.1 RESTATED BY-LAWS OF CIGNA CORPORATION (A Delaware Corporation) ARTICLE I Offices Section 1.Registered Office. The registered office of the Corporation within the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2.Other Offices. The Corporation may also have offices at such other places, both within and without the State of Delaware, as the Board of Di

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 20, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 8

Cigna Announces Leadership Changes to Continue Accelerating Business Growth

Exhibit 99.1 Press Release Cigna Announces Leadership Changes to Continue Accelerating Business Growth ? Eric Palmer promoted to president and chief executive officer, Evernorth ? Paul Sanford promoted to executive vice president, operations, Cigna Corporation ? Noelle Eder assumes leadership of global data, analytics, and automation as executive vice president and global chief information officer

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2021 Cigna Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82

Amendment No. 2 to the Express Scripts, Inc. Executive Deferred Compensation Plan

Exhibit 10.3 AMENDMENT NO. 2 TO THE EXPRESS SCRIPTS, INC. EXECUTIVE DEFERRED COMPENSATION PLAN (As amended and restated effective December 20, 2018) WHEREAS, Cigna Corporation (the ?Company?) sponsors the Express Scripts Inc. Executive Deferred Compensation Plan (the ?Plan?) for the benefit of a select group of one or more management or highly compensated employees; and WHEREAS, the Company desire

As filed with the Securities and Exchange Commission on August 5, 2021

As filed with the Securities and Exchange Commission on August 5, 2021 Registration No.